Product NDC: | 0378-5053 |
Proprietary Name: | Carbidopa and Levodopa |
Non Proprietary Name: | carbidopa and levodopa |
Active Ingredient(s): | 25; 250 mg/1; mg/1 & nbsp; carbidopa and levodopa |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, ORALLY DISINTEGRATING |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0378-5053 |
Labeler Name: | Mylan Pharmaceuticals Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA078893 |
Marketing Category: | ANDA |
Start Marketing Date: | 20121019 |
Package NDC: | 0378-5053-05 |
Package Description: | 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-5053-05) |
NDC Code | 0378-5053-05 |
Proprietary Name | Carbidopa and Levodopa |
Package Description | 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-5053-05) |
Product NDC | 0378-5053 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | carbidopa and levodopa |
Dosage Form Name | TABLET, ORALLY DISINTEGRATING |
Route Name | ORAL |
Start Marketing Date | 20121019 |
Marketing Category Name | ANDA |
Labeler Name | Mylan Pharmaceuticals Inc. |
Substance Name | CARBIDOPA; LEVODOPA |
Strength Number | 25; 250 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA] |